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Introduction: JNJ-26489112 appeared in animal models as a cen-
trally active, broad spectrum anticonvulsant. A Phase-IIa placebo-
controlled, single-blind Proof of Concept study was performed to 
explore dose-related anticonvulsant effects in epilepsy patients.
Patients (or Materials) and Methods: Twelve adult Caucasian 
patients (3 men, 9 women; age, 18–40) with idiopathic photosensi-
tive epilepsy underwent standardized photic stimulation during scalp 
EEG recording. Photosensitivity ranges (SPR) were determined before 
and at hourly intervals for up to 8 hours and at 12 hours after receiv-
ing a single oral dose of placebo on day 1, JNJ-26489112 on day 
2, and a second dose of placebo on day 3. One patient withdrew 
after day 1. A positive response was defined as abolishment of the 
epileptogenic response or reduction in at least 3 out of 4 consecu-
tive time points on either day 2 or day 3 compared with baseline 
day 1. The difference in SPR at each time point on day 2 and day 3 
were calculated relative to matched time points on day 1 and plot-
ted versus time for each patient. The type of response (ie, positive 
response or complete suppression) and number of responders were 
summarized by dose level. Cohorts of 4 patients were dosed 1000, 
2000, or 3000 mg, respectively, and blood samples taken after each 
EEG photosensitivity measure. Safety was assessed by the reporting 
of adverse events, vital signs, 12-lead ECG, physical and neurological 
examinations, and laboratory assessments.
Results: Ten of 11 patients (91%) showed a clear pharmacodynamic 
effect starting on dosing day 2, with a dose-dependency for complete 
suppression.The median Tmax of JNJ-26489112 (range, 3.73–5.04 
hours) in plasma was similar across all 3 dose groups and plasma 
exposure increased proportionally with dose; concentrations of 
other AEDs did not appear to be effected by coadministration of 
JNJ-26489112. Most frequent adverse events reported being mild 
headache, dizziness, and nausea.
Conclusion: Single oral doses of JNJ-26489112 were well tolerated 
and exhibited dose-related antiepileptic effects in patients with idi-
opathic, photosensitive epilepsy.
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Introduction: Increased heart rate is a significant predictor of death 
and hospitalization in heart failure patients. Risk increases directly 
with increasing heart rate above 60 beats/min. These lead to the 
hypothesis that lowering heart rate with the If inhibitor, ivabradine, 
could be beneficial for cardiac function and clinical outcomes in heart 
failure patients.
Patients (or Materials) and Methods: A total of 309 stable IHF 
patients attending Sultan Qaboos University Hospital, Cardiology 
Clinic, were screened. Qualified patients were enrolled in the study 
and were randomly allocated to 2 groups: carvedilol up to 25 mg BID 
(group I) and carvedilol/ivabradine up to 25/7.5 mg BID (group II). 
The duration of follow-up was 6 months. The average daily dose of 
ivabradine was 5.8 mg. The average daily dose of carvedilol was 16.2 
mg and 11.4 mg in group I and in group II respectively.
Results: Resting HR decreased in both groups from 82.6 (12) to 
72.9 (12.7) beats/min in group 1 (P = 0.05); and from 85.3 (9.7) to 
68.5 (9.4) beats/min in group II (P = 0.05). The reduction in HR was 
significantly higher in the combination group [(diff = 7.3 beats/min, P 
= 0.03)]. There was a significant increment in left ventricular ejection 
fraction (LVEF) in group II by 4.6 (5.9)% (P = 0.01), whereas no 
significant change was observed in group I. The reduction in HR due 
to ivabradine was associated with pronounced increment in health-
related quality of life and reduction of incidence of admission events 
to hospital with worsening heart failure. Ivabradine in combination 
with carvedilol was associated with nonsignificant asymptomatic 
bradycardia (P = 0.08).
Conclusion: Combining ivabradine to carvedilol in stable ischemic 
heart failure patients with heart rate faster than 70 beats/min was 
associated with better heart rate reduction, improvement of quality 
of life, and reduced rehospitalization. Risk of bradycardia should 
be taken in consideration when ivabradine is used with carvedilol
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Introduction: Combining the regulatory requirement to obtain 
human mass balance and metabolism data along with determin-
ing absolute oral bioavailability and clearance data for new drugs 
requires an ability to formulate and manufacture both intravenous 
and oral drug products at microtracer and therapeutic doses, respec-
tively, along with the ability to correctly implement accelerator mass 
spectrometry (AMS) to provide the differential analysis required for 
14C intravenous drug product.
Patients (or Materials) and Methods: We will describe variations of 
integrated study design, combining intravenous microtracer doses 
with the conventional human mass balance study either as a crossover 
study in the same subjects or as a parallel group study in separate 
cohorts of subjects to deliver a material, time and cost efficient study 
that is rich in PK and metabolism data to support regulatory sub-
mission. In the microtracer part of the study, intravenous levels of 
14C parent drug are generated by AMS analysis and absolute bio-
availability data is generated by comparison against conventional 
liquid chromatography-mass spectrometry (LC-MS/MS) analysis of 
unlabeled orally administered drug. Mass balance data are generated 
after administration of a 14C labeled oral dose in a second period 
of the study utilizing liquid scintillation counting to determine 14C 
recovery from excreta. Metabolite profiling and identification is also 
performed from the samples collected at this part of the study.
Results: A variety of study designs and summary data from com-
pleted studies will be reviewed, and the benefits and merits of the 
design over conventional approaches to generate such data will be 
discussed. This will include evaluation of time and dose-dependent 
